The economic footprint of a truly historic pharmaceutical blockbuster extends far beyond corporate balance sheets; it acts as a sovereign macroeconomic engine. When a single molecule commands billions in annual global trade, it reshapes the economic architecture of its home nation. In countries like Denmark, the meteoric expansion of Novo Nordisk’s metabolic portfolio has fundamentally…
Free Membership Required
You must be a Free member to access this content.
Already a member? Log in here
